1
Medical data is for informational purposes only. You should always consult your family physician, or one of our referral physicians prior to treatment.
Supplement to
The Art of Getting Well
DMSO
(Dimethylsulfoxide)
Treatments
in Arthritis
Sources are given in references.
Authors of contributions\quotations are alphabetically arranged;
major author, if any, is underlined.
Jack Blount, M.D., Thomas McPherson Brown, M.D., Ronald
M. Davis, M.D., Ray Evers, M.D., Stanley Wallace Jacob, M.D., Pat
McGrady, Sr., Efrain Olszewer, M.D., Gus J. Prosch, Jr., M.D., Dr.
Paul K. Pybus, Fuad C. Sabbag, M.D., Roger Wyburn-Mason, M.D.,
Ph.D., Alan Rory Zapata, M.D./Responsible editor/writer Anthony di
Fabio.
All rights reserved by the The Roger Wyburn-Mason and Jack M.Blount
Foundation for Eradication of Rheumatoid Disease
AKA The Arthritis Trust of America
®
7376 Walker Road, Fairview, Tn 37062
Effrain Olszewer, M.D.
Several years ago Ronald M. Davis, M.D. demonstrated, in our
publication A Treatment for Scleroderma & Lupus Erythematosus,
the strategic use of DMSO (Dimethylsulfoxide). [See http://
www.arthritistrust.org] We've also reported on the good results of
DMSO used with and without EDTA (Ethylene Diamine Tetracetic
Acid) in our Chelation Therapy. [See http://www.arthritistrust.org]
DMSO is a prolific, and inexpensive byproduct of the pulp paper
industry, and its medical uses has been reported many times, by many
people, but especially in the works of chemist Robert J. Herschler and
surgeon Stanley Wallace Jacob, M.D., and also as popularized by Pat
McGrady, Sr. in The Persecuted Drug: The Story of DMSO
13
.
The external and internal use of DMSO by veterinarians for pain
in animals has long been accepted. Those humans who've managed
to obtain a sufficiently pure variety of DMSO have also benefited from
its pain-relieving qualities. Apparently, as Ronald M. Davis, M.D. has
learned, when used in an IV over a number of months, even the most
hopeless cases of Scleroderma and Lupus Erythematosus can be
drastically reversed; while its use (as developed by Ray Evers, M.D.
(deceased) in EDTA/DMSO IV's has long been accepted by many
holistic physicians for peripheral circulation problems, as well as
many other problems all of which are related -- as is Scleroderma and
Lupus Erythematosus -- to free radical excess in the human phsyiological
systems.
Those of us who've suffered from Rheumatoid Diseases of one
or the other of the 75 to 100 differently named collagen tissue diseases
know the nature of free radical pathology first hand. We could not, on
the best of days, dispute that collagen tissue diseases (Rheumatoid
Diseases) generate as a by-product many free radicals which create
hob with every working apparatus of our human bodies.
The message to be learned from the pioneer physicians Jack
Blount, M.D., Thomas McPherson Brown, M.D., Ronald Davis,
M.D., Efrain Olszewer, M.D., Ray Evers, M.D., Stanley Jacobs,
Roger Wyburn-Mason, M.D., Ph.D., Gus Prosch, Jr., M.D., Dr. Paul
K. Pybus, Fuad C. Sabbag, M.D., Alan Rory Zapata, M.D. and others
is that (1) collagen tissue diseases can be licked; (2) the pain of these
diseases do not need to be endured; (3) one does not need to destroy
self with the use of cytotoxic drugs, gold, penicillamine or long-term
corticosteroids to rid oneself of the disease and its effects. Indeed, we
have now learned that all of these traditional rheumatic treatments
generate more dangeorus free-radicals than the disease itself, thus
over-burdening the body even further.
It is clear, in the reports that follow, that Doctors Olszewer,
Sabbag and Zapata, along with Jacobs, Evers and Davis, have added
new and important knowledge to our persisent search for wellness.
Anthony di Fabio
Control of Free Radicals in
Rheumatoid Arthritis and Osteoarthritis
Efrain Olszewer, M.D., Fuad C. Sabbag, M.D.,
Alan Rory Zapata, M.D.
Copyright Townsend letter for Doctors, June 1922, #107, p.495; re-
Figure 1: Relationship Between FR Synthesis (by HLB Test) in Patients with Rheumatoid Disease,
Under Antioxidant Therapy Using DMSO
Percent of FR Synthesis
Therapy
Before (30.6%)
Immediately After (10.6%)
After 18 Months (13.3%)
40
30
1111111
1111111
20
1111111
1111111
[[[[[[[[
10
1111111
0000000
[[[[[[[[
1111111
0000000
[[[[[[[[
0
1111111
0000000
[[[[[[[[
®